|Bid||428.00 x 0|
|Ask||428.25 x 0|
|Day's Range||417.50 - 430.50|
|52 Week Range||212.70 - 447.95|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||33.04|
|Forward Dividend & Yield||7.00 (1.66%)|
|Ex-Dividend Date||Mar 23, 2020|
|1y Target Est||444.39|
Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.
India's Zydus Cadila said on Wednesday its COVID-19 vaccine candidate was found to be safe and well-tolerated in an early-stage human trial. The company will now start a mid-stage trial of the vaccine candidate, ZyCoV-D, in over 1,000 healthy adult volunteers from Thursday to test its effectiveness, it said in a regulatory filing. The safety of the vaccine candidate in volunteers enrolled in the early-stage trial, who were administered doses since July 15, was endorsed by an independent data safety monitoring board.
India's Zydus Cadila plans to complete late-stage trials for its novel coronavirus vaccine candidate by February or March and could produce up to 100 million doses a year initially if it is successful, the company chairman said Friday. Cadila's vaccine candidate, known as ZyCov-D, is one of dozens being developed around the world to fight the coronavirus pandemic. "We are looking at about seven or a little more than seven months for the vaccine, provided the data is encouraging and the vaccine is proven to be effective during the trials," Chairman Pankaj Patel told Reuters in an interview.